Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

Trump is rounding out his health cabinet with another controversial figure: one of the authors of the Great Barrington ...

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

Career conservative and former congressman Dave Weldon will, if confirmed, act as director of the Centers of Disease Control ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...